{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:52:11Z","timestamp":1790625131912,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,8,21]],"date-time":"2018-08-21T00:00:00Z","timestamp":1534809600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"SANOFI-GENZYME","award":["GZ-2010-10458"],"award-info":[{"award-number":["GZ-2010-10458"]}]},{"name":"Association Vaincre les Maladies Lysosomales","award":["VML S9MBerger"],"award-info":[{"award-number":["VML S9MBerger"]}]},{"name":"CHU Clermont-Ferrand","award":["PHRC2010-AOI MBerger"],"award-info":[{"award-number":["PHRC2010-AOI MBerger"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s40262-018-0708-8","type":"journal-article","created":{"date-parts":[[2018,8,21]],"date-time":"2018-08-21T01:47:46Z","timestamp":1534816066000},"page":"469-482","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Intra-monocyte Pharmacokinetics of Imiglucerase Supports a Possible Personalized Management of Gaucher Disease Type 1"],"prefix":"10.1007","volume":"58","author":[{"given":"Juliette","family":"Berger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Vigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thu Thuy","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roseline","family":"Froissart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Belmatoug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Dalbi\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agathe","family":"Masseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Serratrice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves-Marie","family":"Pers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Bertchansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Camou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monia","family":"Bengherbia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Bourgne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Caillaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Pettazzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Berrahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Stirnemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"France","family":"Mentr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1858-0587","authenticated-orcid":false,"given":"Marc G.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,21]]},"reference":[{"key":"708_CR1","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","volume":"372","author":"GA Grabowski","year":"2008","unstructured":"Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher\u2019s disease. Lancet. 2008;372:1263\u201371.","journal-title":"Lancet"},{"key":"708_CR2","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","volume":"324","author":"NW Barton","year":"1991","unstructured":"Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, et al. Replacement therapy for inherited enzyme deficiency: macrophage-targeted glucocerebrosidase for Gaucher\u2019s disease. N Engl J Med. 1991;324:1464\u201370.","journal-title":"N Engl J Med"},{"key":"708_CR3","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/S0002-9343(02)01150-6","volume":"113","author":"NJ Weinreb","year":"2002","unstructured":"Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5\u00a0years of treatment: a report from the Gaucher Registry. Am J Med. 2002;113:112\u20139.","journal-title":"Am J Med"},{"key":"708_CR4","doi-asserted-by":"publisher","first-page":"4651","DOI":"10.1182\/blood-2010-02-268649","volume":"115","author":"A Zimran","year":"2010","unstructured":"Zimran A, Altarescu G, Philips M, Attias D, Jmoudiak M, Deeb M, et al. Phase 1\/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience. Blood. 2010;115:4651\u20136.","journal-title":"Blood"},{"key":"708_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/glycob\/cwp138","volume":"20","author":"B Brumshtein","year":"2010","unstructured":"Brumshtein B, Salinas P, Peterson B, Chan V, Silman I, Sussman JL, et al. Characterization of gene-activated human acid-beta-glucosidase: crystal structure, glycan composition, and internalization into macrophages. Glycobiology. 2010;20:24\u201332.","journal-title":"Glycobiology"},{"key":"708_CR6","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/j.1467-7652.2007.00263.x","volume":"5","author":"Y Shaaltiel","year":"2007","unstructured":"Shaaltiel Y, Bartfeld D, Hashmueli S, Baum G, Brill-Almon E, Galili G, et al. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher\u2019s disease using a plant cell system. Plant Biotechnol J. 2007;5:579\u201390.","journal-title":"Plant Biotechnol J"},{"key":"708_CR7","doi-asserted-by":"publisher","first-page":"5767","DOI":"10.1182\/blood-2011-07-366955","volume":"118","author":"A Zimran","year":"2011","unstructured":"Zimran A, Brill-Almon E, Chertkoff R, Petakov M, Blanco-Favela F, Mu\u00f1oz ET, et al. Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood. 2011;118:5767\u201373.","journal-title":"Blood"},{"key":"708_CR8","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1056\/NEJM199212033272304","volume":"327","author":"ML Figueroa","year":"1992","unstructured":"Figueroa ML, Rosenbloom BE, Kay AC, Garver P, Thurston DW, Koziol JA, et al. A less costly regimen of alglucerase to treat Gaucher\u2019s disease. N Engl J Med. 1992;327:1632\u20136.","journal-title":"N Engl J Med"},{"key":"708_CR9","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s10545-012-9528-4","volume":"36","author":"NJ Weinreb","year":"2013","unstructured":"Weinreb NJ, Goldblatt J, Villalobos J, Charrow J, Cole JA, Kerstenetzky M, et al. Long-term clinical outcomes in type 1 Gaucher disease following 10\u00a0years of imiglucerase treatment. J Inherit Metab Dis. 2013;36:543\u201353.","journal-title":"J Inherit Metab Dis"},{"key":"708_CR10","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/jcb.240570205","volume":"57","author":"GJ Murray","year":"1995","unstructured":"Murray GJ, Oliver KL, Jin FS, Brady RO. Studies on the turnover of exogenous mannose-terminal glucocerebrosidase in rat liver lysosomes. J Cell Biochem. 1995;57:208\u201317.","journal-title":"J Cell Biochem"},{"key":"708_CR11","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1203\/00006450-199602000-00021","volume":"39","author":"YH Xu","year":"1996","unstructured":"Xu YH, Ponce E, Sun Y, Leonova T, Bove K, Witte D, et al. Turnover and distribution of intravenously administered mannose-terminated human acid beta-glucosidase in murine and human tissues. Pediatr Res. 1996;39:313\u201322.","journal-title":"Pediatr Res"},{"key":"708_CR12","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/j.1432-1033.1996.00344.x","volume":"237","author":"MK Bijsterbosch","year":"1996","unstructured":"Bijsterbosch MK, Donker W, van de Bilt H, van Weely S, van Berkel TJ, Aerts JM. Quantitative analysis of the targeting of mannose-terminal glucocerebrosidase: predominant uptake by liver endothelial cells. Eur J Biochem. 1996;237:344\u20139.","journal-title":"Eur J Biochem"},{"key":"708_CR13","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1016\/S0140-6736(96)04451-0","volume":"348","author":"PK Mistry","year":"1996","unstructured":"Mistry PK, Wraight EP, Cox TM. Therapeutic delivery of proteins to macrophages: implications for treatment of Gaucher\u2019s disease. Lancet. 1996;348:1555\u20139.","journal-title":"Lancet"},{"key":"708_CR14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1053\/j.seminhematol.2004.07.010","volume":"41","author":"NJ Weinreb","year":"2004","unstructured":"Weinreb NJ, Aggio MC, Andersson HC, Andria G, Charrow J, Clarke JTR, et al. Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin Hematol. 2004;41:15\u201322.","journal-title":"Semin Hematol"},{"key":"708_CR15","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1182\/blood-2011-04-308890","volume":"118","author":"A Zimran","year":"2011","unstructured":"Zimran A. How I treat Gaucher disease. Blood. 2011;118:1463\u201371.","journal-title":"Blood"},{"key":"708_CR16","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/j.1399-0004.2008.00978.x","volume":"73","author":"KB Sims","year":"2008","unstructured":"Sims KB, Pastores GM, Weinreb NJ, Barranger J, Rosenbloom BE, Packman S, et al. Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. Clin Genet. 2008;73:430\u201340.","journal-title":"Clin Genet"},{"key":"708_CR17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1750-1172-7-77","volume":"7","author":"J Stirnemann","year":"2012","unstructured":"Stirnemann J, Vigan M, Hamroun D, Heraoui D, Rossi-Semerano L, Berger MG, et al. The French Gaucher\u2019s disease registry: clinical characteristics, complications and treatment of 562 patients. Orphanet J Rare Dis. 2012;7:77.","journal-title":"Orphanet J Rare Dis"},{"key":"708_CR18","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1517\/14656560903270520","volume":"10","author":"CEM Hollak","year":"2009","unstructured":"Hollak CEM, de Fost M, van Dussen L, Vom Dahl S, Aerts JMFG. Enzyme therapy for the treatment of type 1 Gaucher disease: clinical outcomes and dose-response relationships. Expert Opin Pharmacother. 2009;10:2641\u201352.","journal-title":"Expert Opin Pharmacother"},{"key":"708_CR19","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/GIM.0b013e31818e2c19","volume":"11","author":"GA Grabowski","year":"2009","unstructured":"Grabowski GA, Kacena K, Cole JA, Hollak CEM, Zhang L, Yee J, et al. Dose-response relationships for enzyme replacement therapy with imiglucerase\/alglucerase in patients with Gaucher disease type 1. Genet Med. 2009;11:92\u2013100.","journal-title":"Genet Med"},{"key":"708_CR20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.bcmd.2010.05.002","volume":"46","author":"J Goldblatt","year":"2011","unstructured":"Goldblatt J, Fletcher JM, McGill J, Szer J, Wilson M. Enzyme replacement therapy \u201cdrug holiday\u201d: results from an unexpected shortage of an orphan drug supply in Australia. Blood Cells Mol Dis. 2011;46:107\u201310.","journal-title":"Blood Cells Mol Dis"},{"key":"708_CR21","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.bcmd.2010.09.005","volume":"46","author":"P Giraldo","year":"2011","unstructured":"Giraldo P, Ir\u00fan P, Alfonso P, Dalmau J, Fern\u00e1ndez-Gal\u00e1n MA, Figueredo A, et al. Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage. Blood Cells Mol Dis. 2011;46:115\u20138.","journal-title":"Blood Cells Mol Dis"},{"key":"708_CR22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/8904_2012_158","volume":"7","author":"L Deroma","year":"2013","unstructured":"Deroma L, Sechi A, Dardis A, Macor D, Liva G, Ciana G, et al. Did the temporary shortage in supply of imiglucerase have clinical consequences? Retrospective observational study on 34 italian Gaucher type I patients. JIMD Rep. 2013;7:117\u201322.","journal-title":"JIMD Rep"},{"key":"708_CR23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13023-015-0275-0","volume":"10","author":"J Stirnemann","year":"2015","unstructured":"Stirnemann J, Rose C, Serratrice C, Dalbies F, Lidove O, Masseau A, et al. Impact of imiglucerase supply constraint on the therapeutic management and course of disease in French patients with Gaucher disease type 1. Orphanet J Rare Dis. 2015;10:62.","journal-title":"Orphanet J Rare Dis"},{"key":"708_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.bcmd.2009.09.006","volume":"44","author":"CEM Hollak","year":"2010","unstructured":"Hollak CEM, vom Dahl S, Aerts JMFG, Belmatoug N, Bembi B, Cohen Y, et al. Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. Blood Cells Mol Dis. 2010;44:41\u20137.","journal-title":"Blood Cells Mol Dis"},{"key":"708_CR25","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-2141.2010.08214.x","volume":"150","author":"J Berger","year":"2010","unstructured":"Berger J, Lecourt S, Vanneaux V, Rapatel C, Boisgard S, Caillaud C, et al. Glucocerebrosidase deficiency dramatically impairs human bone marrow haematopoiesis in an in vitro model of Gaucher disease. Br J Haematol. 2010;150:93\u2013101.","journal-title":"Br J Haematol"},{"key":"708_CR26","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1365-2141.2011.08989.x","volume":"157","author":"J Berger","year":"2012","unstructured":"Berger J, Stirnemann J, Bourgne C, Pereira B, Pigeon P, Heraoui D, et al. The uptake of recombinant glucocerebrosidases by blood monocytes from type 1 Gaucher disease patients is variable. Br J Haematol. 2012;157:274\u20137.","journal-title":"Br J Haematol"},{"key":"708_CR27","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/0003-9861(76)90547-6","volume":"175","author":"SP Peters","year":"1976","unstructured":"Peters SP, Coyle P, Glew RH. Differentiation of beta-glucocerebrosidase from beta-glucosidase in human tissues using sodium taurocholate. Arch Biochem Biophys. 1976;175:569\u201382.","journal-title":"Arch Biochem Biophys"},{"key":"708_CR28","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1172\/JCI117084","volume":"93","author":"CE Hollak","year":"1994","unstructured":"Hollak CE, van Weely S, van Oers MH, Aerts JM. Marked elevation of plasma chitotriosidase activity: a novel hallmark of Gaucher disease. J Clin Investig. 1994;93:1288\u201392.","journal-title":"J Clin Investig"},{"key":"708_CR29","doi-asserted-by":"publisher","first-page":"e0181700","DOI":"10.1371\/journal.pone.0181700","volume":"12","author":"M Pettazzoni","year":"2017","unstructured":"Pettazzoni M, Froissart R, Pagan C, Vanier MT, Ruet S, Latour P, et al. LC-MS\/MS multiplex analysis of lysosphingolipids in plasma and amniotic fluid: a novel tool for the screening of sphingolipidoses and Niemann-Pick type C disease. PLoS One. 2017;12:e0181700.","journal-title":"PLoS One"},{"key":"708_CR30","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/GIM.0b013e3181c39194","volume":"12","author":"NJ Weinreb","year":"2010","unstructured":"Weinreb NJ, Cappellini MD, Cox TM, Giannini EH, Grabowski GA, Hwu W-L, et al. A validated disease severity scoring system for adults with type 1 Gaucher disease. Genet Med. 2010;12:44\u201351.","journal-title":"Genet Med"},{"key":"708_CR31","doi-asserted-by":"crossref","unstructured":"Pag\u00e8s J. Multiple factor analysis by example using R: Chapman and Hall\/CRC, The R Series; 2014","DOI":"10.1201\/b17700"},{"key":"708_CR32","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/psp4.12161","volume":"6","author":"THT Nguyen","year":"2017","unstructured":"Nguyen THT, Mouksassi M-S, Holford N, Al-Huniti N, Freedman I, Hooker AC, et al. Model evaluation of continuous data pharmacometric models: metrics and graphics. CPT Pharmacomet Syst Pharmacol. 2017;6:87\u2013109.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"708_CR33","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1097\/ALN.0b013e3181d47604","volume":"112","author":"P Ray","year":"2010","unstructured":"Ray P, Le Manach Y, Riou B, Houle TT. Statistical evaluation of a biomarker. Anesthesiology. 2010;112:1023\u201340.","journal-title":"Anesthesiology"},{"issue":"5","key":"708_CR34","doi-asserted-by":"publisher","first-page":"e00071","DOI":"10.1042\/BSR20130081","volume":"33","author":"Y Tekoah","year":"2013","unstructured":"Tekoah Y, Tzaban S, Kizhner T, Hainrichson M, Gantman A, Golembo M, et al. Glycosylation and functionality of recombinant \u03b2-glucocerebrosidase from various production systems. Biosci Rep. 2013;33(5):e00071.","journal-title":"Biosci Rep"},{"key":"708_CR35","doi-asserted-by":"publisher","first-page":"e10750","DOI":"10.1371\/journal.pone.0010750","volume":"5","author":"Y-H Xu","year":"2010","unstructured":"Xu Y-H, Sun Y, Barnes S, Grabowski GA. Comparative therapeutic effects of velaglucerase alfa and imiglucerase in a Gaucher disease mouse model. PLoS One. 2010;5:e10750.","journal-title":"PLoS One"},{"key":"708_CR36","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1177\/43.2.7822772","volume":"43","author":"GJ Murray","year":"1995","unstructured":"Murray GJ, Jin FS. Immunoelectron microscopic localization of mannose-terminal glucocerebrosidase in lysosomes of rat liver Kupffer cells. J Histochem Cytochem. 1995;43:149\u201358.","journal-title":"J Histochem Cytochem"},{"key":"708_CR37","doi-asserted-by":"publisher","first-page":"e0170268","DOI":"10.1371\/journal.pone.0170268","volume":"12","author":"WW Kallemeijn","year":"2017","unstructured":"Kallemeijn WW, Scheij S, Hoogendoorn S, Witte MD, Herrera Moro Chao D, van Roomen CPAA, et al. Investigations on therapeutic glucocerebrosidases through paired detection with fluorescent activity-based probes. PLoS One. 2017;12:e0170268.","journal-title":"PLoS One"},{"key":"708_CR38","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40262-016-0387-2","volume":"55","author":"E Gras-Colomer","year":"2016","unstructured":"Gras-Colomer E, Mart\u00ednez-G\u00f3mez MA, Moya-Gil A, Fernandez-Zarzoso M, Merino-Sanjuan M, Climente-Mart\u00ed M. Cellular uptake of glucocerebrosidase in Gaucher patients receiving enzyme replacement treatment. Clin Pharmacokinet. 2016;55:1103\u201313.","journal-title":"Clin Pharmacokinet"},{"key":"708_CR39","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1084\/jem.143.4.975","volume":"143","author":"E Beutler","year":"1976","unstructured":"Beutler E, Kuhl W, Matsumoto F, Pangalis G. Acid hydrolases in leukocytes and platelets of normal subjects and in patients with Gaucher\u2019s and Fabry\u2019s disease. J Exp Med. 1976;143:975\u201380.","journal-title":"J Exp Med"},{"key":"708_CR40","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1182\/blood.V89.9.3412","volume":"89","author":"M Lorincz","year":"1997","unstructured":"Lorincz M, Herzenberg LA, Diwu Z, Barranger JA, Kerr WG. Detection and isolation of gene-corrected cells in Gaucher disease via a fluorescence-activated cell sorter assay for lysosomal glucocerebrosidase activity. Blood. 1997;89:3412\u201320.","journal-title":"Blood"},{"key":"708_CR41","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJM197411072911901","volume":"291","author":"RO Brady","year":"1974","unstructured":"Brady RO, Pentchev PG, Gal AE, Hibbert SR, Dekaban AS. Replacement therapy for inherited enzyme deficiency: use of purified glucocerebrosidase in Gaucher\u2019s disease. N Engl J Med. 1974;291:989\u201393.","journal-title":"N Engl J Med"},{"key":"708_CR42","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1093\/glycob\/cwm008","volume":"17","author":"SM Patten Van","year":"2007","unstructured":"Van Patten SM, Hughes H, Huff MR, Piepenhagen PA, Waire J, Qiu H, et al. Effect of mannose chain length on targeting of glucocerebrosidase for enzyme replacement therapy of Gaucher disease. Glycobiology. 2007;17:467\u201378.","journal-title":"Glycobiology"},{"key":"708_CR43","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1172\/JCI116409","volume":"91","author":"Y Sato","year":"1993","unstructured":"Sato Y, Beutler E. Binding, internalization, and degradation of mannose-terminated glucocerebrosidase by macrophages. J Clin Investig. 1993;91:1909\u201317.","journal-title":"J Clin Investig"},{"key":"708_CR44","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/icb.2008.90","volume":"87","author":"C Varol","year":"2009","unstructured":"Varol C, Yona S, Jung S. Origins and tissue-context-dependent fates of blood monocytes. Immunol Cell Biol. 2009;87:30\u20138.","journal-title":"Immunol Cell Biol"},{"key":"708_CR45","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1084\/jem.20170355","volume":"214","author":"AA Patel","year":"2017","unstructured":"Patel AA, Zhang Y, Fullerton JN, Boelen L, Rongvaux A, Maini AA, et al. The fate and lifespan of human monocyte subsets in steady state and systemic inflammation. J Exp Med. 2017;214:1913\u201323.","journal-title":"J Exp Med"},{"key":"708_CR46","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.bcmd.2015.05.009","volume":"55","author":"JM Mucci","year":"2015","unstructured":"Mucci JM, Cuello MF, Kisinovsky I, Larroude M, Delpino MV, Rozenfeld PA. Proinflammatory and proosteoclastogenic potential of peripheral blood mononuclear cells from Gaucher patients: Implication for bone pathology. Blood Cells Mol Dis. 2015;55:134\u201343.","journal-title":"Blood Cells Mol Dis"},{"key":"708_CR47","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s00277-015-2354-7","volume":"94","author":"F Vairo","year":"2015","unstructured":"Vairo F, Sperb-Ludwig F, Wilke M, Michellin-Tirelli K, Netto C, Neto EC, et al. Osteopontin: a potential biomarker of Gaucher disease. Ann Hematol. 2015;94:1119\u201325.","journal-title":"Ann Hematol"},{"key":"708_CR48","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1189\/jlb.1106711","volume":"81","author":"TH Burdo","year":"2007","unstructured":"Burdo TH, Wood MR, Fox HS. Osteopontin prevents monocyte recirculation and apoptosis. J Leukoc Biol. 2007;81:1504\u201311.","journal-title":"J Leukoc Biol"},{"key":"708_CR49","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/ajh.24491","volume":"91","author":"V Murugesan","year":"2016","unstructured":"Murugesan V, Chuang W-L, Liu J, Lischuk A, Kacena K, Lin H, et al. Glucosylsphingosine is a key biomarker of Gaucher disease. Am J Hematol. 2016;91:1082\u20139.","journal-title":"Am J Hematol"},{"key":"708_CR50","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1006\/bcmd.1998.0172","volume":"24","author":"H Ida","year":"1998","unstructured":"Ida H, Rennert OM, Ito T, Maekawa K, Eto Y. Type 1 Gaucher disease: phenotypic expression and natural history in Japanese patients. Blood Cells Mol Dis. 1998;24:73\u201381.","journal-title":"Blood Cells Mol Dis"},{"key":"708_CR51","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1023\/A:1005655031239","volume":"23","author":"P Maaswinkel-Mooij","year":"2000","unstructured":"Maaswinkel-Mooij P, Hollak C, van Eysden-Plaisier M, Prins M, Aerts H, P\u00f6ll R. The natural course of Gaucher disease in The Netherlands: implications for monitoring of disease manifestations. J Inherit Metab Dis. 2000;23:77\u201382.","journal-title":"J Inherit Metab Dis"},{"key":"708_CR52","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.bcmd.2009.08.002","volume":"43","author":"S Piran","year":"2009","unstructured":"Piran S, Roberts A, Patterson MA, Amato D. The clinical course of untreated Gaucher disease in 22 patients over 10\u00a0years: hematological and skeletal manifestations. Blood Cells Mol Dis. 2009;43:289\u201393.","journal-title":"Blood Cells Mol Dis"},{"key":"708_CR53","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1001\/archinternmed.2010.302","volume":"170","author":"M Balwani","year":"2010","unstructured":"Balwani M, Fuerstman L, Kornreich R, Edelmann L, Desnick RJ. Type 1 Gaucher disease: significant disease manifestations in \u201casymptomatic\u201d homozygotes. Arch Intern Med. 2010;170:1463\u20139.","journal-title":"Arch Intern Med"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-018-0708-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-018-0708-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-018-0708-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T11:56:28Z","timestamp":1720526188000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-018-0708-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,21]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["708"],"URL":"https:\/\/doi.org\/10.1007\/s40262-018-0708-8","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,21]]},"assertion":[{"value":"21 August 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study was supported by grants from Genzyme SA then Sanofi-Genzyme (Grant no. GZ-2010-10458) and from Vaincre les Maladies Lysosomales (patient association, Paris, France) (Grant no. VML S9MBerger) and research funding from CHU de Clermont-Ferrand as the promotor establishment, Marc G. Berger being an investigator coordinator (Grant no. PHRC2010-AOI MBerger).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Nadia Belmatoug, Christian Rose, Marc G. Berger, and Christine Serratrice received honoraria from Sanofi-Genzyme and Shire Corporation for travel and speaking or expert missions; Yves-Marie Pers and J\u00e9r\u00f4me Stirnemann received travel fees from Sanofi-Genzyme. Nadia Belmatoug, Christian Rose, and Marc G. Berger are scientific leaders of research projects receiving research grants from Sanofi-Genzyme and Shire Corporation. Christian Rose is a scientific leader of a research project receiving research grants from Sanofi-Genzyme. Nadia Belmatoug, Christine Serratrice, Fabrice Camou, and Marc G. Berger are members of the scientific board organized by Sanofi-Genzyme, Shire; Juliette Berger, Marie Vigan, Bruno Pereira, Thu Thuy Nguyen, Roseline Froissart, Florence Dalbi\u00e8s, Agathe Masseau, Yves-Marie Pers, Ivan Bertchansky, Monia Bengherbia, C\u00e9line Bourgne, Catherine Caillaud, Magali Pettazzoni, Amina Berrahal, and France Mentr\u00e9 have no conflicts of interest directly relevant to the contents of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}